Literature DB >> 23255105

Mosaic RASopathies.

Christian Hafner1, Leopold Groesser.   

Abstract

"RASopathies" are a group of developmental syndromes with partly overlapping clinical symptoms that are caused by germline mutations of genes within the Ras/MAPK signaling pathway. Mutations affecting this pathway can also occur in a mosaic state, resulting in congenital syndromes often distinct from those generated by the corresponding germline mutations. For syndromes caused by mosaic mutations of the Ras/MAPK signaling pathway, the term "mosaic RASopathies" has been proposed. In the following article, genetic and phenotypic aspects of mosaic RASopathies will be discussed.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23255105      PMCID: PMC3570515          DOI: 10.4161/cc.23108

Source DB:  PubMed          Journal:  Cell Cycle        ISSN: 1551-4005            Impact factor:   4.534


  72 in total

1.  [Clinical contribution to symptomatology of phacomatosis].

Authors:  G W SCHIMMELPENNING
Journal:  Fortschr Geb Rontgenstr Nuklearmed       Date:  1957-12

2.  Identification of a novel S249C FGFR3 mutation in a keratinocytic epidermal naevus syndrome.

Authors:  L B Ousager; A Bygum; C Hafner
Journal:  Br J Dermatol       Date:  2012-03-27       Impact factor: 9.302

3.  Postzygotic HRAS and KRAS mutations cause nevus sebaceous and Schimmelpenning syndrome.

Authors:  Leopold Groesser; Eva Herschberger; Arno Ruetten; Claudia Ruivenkamp; Enrico Lopriore; Markus Zutt; Thomas Langmann; Sebastian Singer; Laura Klingseisen; Wulf Schneider-Brachert; Agusti Toll; Francisco X Real; Michael Landthaler; Christian Hafner
Journal:  Nat Genet       Date:  2012-06-10       Impact factor: 38.330

4.  RAS mutations are associated with the development of cutaneous squamous cell tumors in patients treated with RAF inhibitors.

Authors:  Patrick A Oberholzer; Damien Kee; Piotr Dziunycz; Antje Sucker; Nyam Kamsukom; Robert Jones; Christine Roden; Clinton J Chalk; Kristin Ardlie; Emanuele Palescandolo; Adriano Piris; Laura E MacConaill; Caroline Robert; Günther F L Hofbauer; Grant A McArthur; Dirk Schadendorf; Levi A Garraway
Journal:  J Clin Oncol       Date:  2011-11-07       Impact factor: 44.544

5.  Segmental neurofibromatosis is caused by somatic mutation of the neurofibromatosis type 1 (NF1) gene.

Authors:  S Tinschert; I Naumann; E Stegmann; A Buske; D Kaufmann; G Thiel; D E Jenne
Journal:  Eur J Hum Genet       Date:  2000-06       Impact factor: 4.246

Review 6.  Squamous cell carcinoma and basal cell carcinoma arising in a naevus sebaceous of Jadassohn: case report and literature review.

Authors:  E A M Ball; M Hussain; A L H Moss
Journal:  Clin Exp Dermatol       Date:  2005-05       Impact factor: 3.470

7.  Schwann cells harbor the somatic NF1 mutation in neurofibromas: evidence of two different Schwann cell subpopulations.

Authors:  E Serra; T Rosenbaum; U Winner; R Aledo; E Ars; X Estivill; H G Lenard; C Lázaro
Journal:  Hum Mol Genet       Date:  2000-12-12       Impact factor: 6.150

8.  Keratinocytic epidermal nevi are associated with mosaic RAS mutations.

Authors:  Christian Hafner; Agusti Toll; Susanne Gantner; Andreas Mauerer; Irene Lurkin; Francesco Acquadro; Alejandro Fernández-Casado; Ellen C Zwarthoff; Wolfgang Dietmaier; Eulalia Baselga; Elisabet Parera; Asunción Vicente; Ariel Casanova; Juan Cigudosa; Thomas Mentzel; Ramon M Pujol; Michael Landthaler; Francisco X Real
Journal:  J Med Genet       Date:  2012-04       Impact factor: 6.318

9.  Dermatological phenotype in Costello syndrome: consequences of Ras dysregulation in development.

Authors:  D H Siegel; J A Mann; A L Krol; K A Rauen
Journal:  Br J Dermatol       Date:  2012-03       Impact factor: 9.302

Review 10.  Costello syndrome: a Ras/mitogen activated protein kinase pathway syndrome (rasopathy) resulting from HRAS germline mutations.

Authors:  Karen W Gripp; Angela E Lin
Journal:  Genet Med       Date:  2012-03       Impact factor: 8.822

View more
  37 in total

1.  Activating HRAS mutation in nevus spilus.

Authors:  Kavita Y Sarin; Jennifer M McNiff; Shirley Kwok; Jinah Kim; Paul A Khavari
Journal:  J Invest Dermatol       Date:  2014-01-03       Impact factor: 8.551

2.  [Nevus spilus: An example of mosaic RASopathy].

Authors:  C Hafner
Journal:  Hautarzt       Date:  2015-05       Impact factor: 0.751

Review 3.  Mosaicism in Cutaneous Disorders.

Authors:  Young H Lim; Zoe Moscato; Keith A Choate
Journal:  Annu Rev Genet       Date:  2017-11-27       Impact factor: 16.830

Review 4.  The ageing genome, clonal mosaicism and chronic disease.

Authors:  Mitchell J Machiela; Stephen J Chanock
Journal:  Curr Opin Genet Dev       Date:  2017-01-06       Impact factor: 5.578

5.  RAS mutations in benign epithelial tumors associated with BRAF inhibitor treatment of melanoma.

Authors:  Jessica C Hassel; Leopold Groesser; Eva Herschberger; Wilko Weichert; Christian Hafner
Journal:  J Invest Dermatol       Date:  2014-07-18       Impact factor: 8.551

6.  Characterization of breakpoint regions of large structural autosomal mosaic events.

Authors:  Mitchell J Machiela; Lea Jessop; Weiyin Zhou; Meredith Yeager; Stephen J Chanock
Journal:  Hum Mol Genet       Date:  2017-11-15       Impact factor: 6.150

Review 7.  The duality of human oncoproteins: drivers of cancer and congenital disorders.

Authors:  Pau Castel; Katherine A Rauen; Frank McCormick
Journal:  Nat Rev Cancer       Date:  2020-04-27       Impact factor: 60.716

8.  Genomic analysis of a case of agminated Spitz nevi and congenital-pattern nevi arising in extensive nevus spilus.

Authors:  Caitlin Porubsky; Jamie K Teer; Yonghong Zhang; Maria Deschaine; Vernon K Sondak; Jane L Messina
Journal:  J Cutan Pathol       Date:  2017-12-17       Impact factor: 1.587

Review 9.  DIAGNOSIS OF ENDOCRINE DISEASE: Mosaic disorders of FGF23 excess: Fibrous dysplasia/McCune-Albright syndrome and cutaneous skeletal hypophosphatemia syndrome.

Authors:  Luis F de Castro; Diana Ovejero; Alison M Boyce
Journal:  Eur J Endocrinol       Date:  2020-05       Impact factor: 6.664

10.  A unique case of multiple non-ossifying fibromas with polyostotic monomelic distribution and aggressive clinical course.

Authors:  Alessandro Corsi; Cristina Remoli; Mara Riminucci; Ernesto Ippolito; John Dimitriou
Journal:  Skeletal Radiol       Date:  2016-11-08       Impact factor: 2.199

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.